Financials Probi AB

Equities

PROB

SE0001280355

Pharmaceuticals

Market Closed - Nasdaq Stockholm 10:32:17 2024-04-26 am EDT 5-day change 1st Jan Change
209 SEK +1.95% Intraday chart for Probi AB +0.97% +2.96%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,529 4,808 4,529 2,324 2,313 2,381 - -
Enterprise Value (EV) 1 2,337 4,637 4,293 2,001 1,983 2,026 1,984 1,938
P/E ratio 29.4 x 51.8 x 54.5 x 57.1 x 137 x 156 x 74.9 x 53.3 x
Yield 0.45% 0.26% 0.33% 0.64% 0.64% 0.72% 0.93% 1.21%
Capitalization / Revenue 4.04 x 6.7 x 6.88 x 3.76 x 3.68 x 3.64 x 3.41 x 3.21 x
EV / Revenue 3.73 x 6.47 x 6.52 x 3.24 x 3.16 x 3.1 x 2.84 x 2.62 x
EV / EBITDA 12.7 x 23.6 x 23.5 x 13.5 x 18.4 x 18.1 x 14.5 x 12.6 x
EV / FCF 16.9 x 46.4 x 77 x 21.9 x 37.9 x 38.2 x 27.6 x 23.6 x
FCF Yield 5.92% 2.16% 1.3% 4.57% 2.64% 2.62% 3.63% 4.23%
Price to Book 2.2 x 4.31 x 3.58 x 1.65 x 1.69 x 1.67 x 1.65 x 1.63 x
Nbr of stocks (in thousands) 11,394 11,394 11,394 11,394 11,394 11,394 - -
Reference price 2 222.0 422.0 397.5 204.0 203.0 209.0 209.0 209.0
Announcement Date 2/11/20 2/9/21 2/2/22 1/27/23 1/26/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 626 717.2 658.2 618.3 627.7 654 699 741
EBITDA 1 183.4 196.5 182.5 148.3 107.5 112.2 137 154
EBIT 1 111.5 123.7 109.2 62.57 11.32 16 41 57
Operating Margin 17.82% 17.25% 16.6% 10.12% 1.8% 2.45% 5.87% 7.69%
Earnings before Tax (EBT) 1 109.5 120.1 107.4 51.97 17.38 19.7 41 58
Net income 1 85.89 92.69 83.14 40.62 16.82 15.2 32 45
Net margin 13.72% 12.92% 12.63% 6.57% 2.68% 2.32% 4.58% 6.07%
EPS 2 7.540 8.140 7.300 3.570 1.480 1.340 2.790 3.920
Free Cash Flow 1 138.5 99.99 55.74 91.5 52.39 53 72 82
FCF margin 22.12% 13.94% 8.47% 14.8% 8.35% 8.1% 10.3% 11.07%
FCF Conversion (EBITDA) 75.5% 50.89% 30.54% 61.72% 48.73% 47.24% 52.55% 53.25%
FCF Conversion (Net income) 161.21% 107.88% 67.04% 225.26% 311.48% 348.68% 225% 182.22%
Dividend per Share 2 1.000 1.100 1.300 1.300 1.300 1.500 1.940 2.530
Announcement Date 2/11/20 2/9/21 2/2/22 1/27/23 1/26/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 170 154.7 174.5 145.1 144 - 156 156.1 151.7 173 162.2 167.2
EBITDA 1 54.07 38.28 45.89 36.32 27.76 - 28.17 19.1 22.01 27.6 33.8 28.8
EBIT 1 34.09 18.49 25.24 14.46 4.383 - 3.989 -5.287 -2.043 3.5 9.8 4.7
Operating Margin 20.05% 11.95% 14.46% 9.97% 3.04% - 2.56% -3.39% -1.35% 2.02% 6.04% 2.81%
Earnings before Tax (EBT) 1 33.41 17.63 25.61 15.35 -6.612 - 6.096 -4.17 1.828 3.5 9.7 4.6
Net income 1 26.27 14.02 19.97 12.36 -5.733 -6.26 6.395 -2.59 1.853 2.6 7.3 3.5
Net margin 15.45% 9.06% 11.44% 8.52% -3.98% - 4.1% -1.66% 1.22% 1.5% 4.5% 2.09%
EPS 2.310 1.230 1.750 1.090 -0.5000 -0.5500 - - - - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 2/2/22 4/26/22 7/15/22 10/21/22 1/27/23 7/18/23 10/24/23 1/26/24 4/23/24 - - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 192 171 236 324 330 355 397 443
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 138 100 55.7 91.5 52.4 53 72 82
ROE (net income / shareholders' equity) 7.88% 8.18% 6.98% 3.04% 1.21% 1.1% 2.2% 3.1%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 101.0 97.90 111.0 124.0 120.0 125.0 126.0 128.0
Cash Flow per Share 15.20 - - - - - - -
Capex 1 35.1 43.4 - 52.4 33.2 25 27 30
Capex / Sales 5.61% 6.05% - 8.48% 5.28% 3.82% 3.86% 4.05%
Announcement Date 2/11/20 2/9/21 2/2/22 1/27/23 1/26/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings